Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted) (2019 - 2026)

Cartesian Therapeutics (RNAC) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$1.46 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 114.71% year-over-year to -$1.46; the TTM value through Mar 2026 reached -$5.91, down 413.91%, while the annual FY2025 figure was -$5.02, 11.8% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$1.46 in Q1 2026 for Cartesian Therapeutics, up from -$3.57 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.54 in Q2 2024 and bottomed at -$41.56 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$3.96, with a median of -$1.13 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 2824.07% in 2022 and then tumbled 83020.0% in 2023.
  • Cartesian Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.05 in 2022, then crashed by 83020.0% to -$41.56 in 2023, then skyrocketed by 100.29% to $0.12 in 2024, then plummeted by 3075.0% to -$3.57 in 2025, then skyrocketed by 59.1% to -$1.46 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$1.46, -$3.57, and -$1.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.